JP7840636B2 - エレヌマブ組成物及びその使用 - Google Patents

エレヌマブ組成物及びその使用

Info

Publication number
JP7840636B2
JP7840636B2 JP2020553476A JP2020553476A JP7840636B2 JP 7840636 B2 JP7840636 B2 JP 7840636B2 JP 2020553476 A JP2020553476 A JP 2020553476A JP 2020553476 A JP2020553476 A JP 2020553476A JP 7840636 B2 JP7840636 B2 JP 7840636B2
Authority
JP
Japan
Prior art keywords
erenumab
composition
variant
variants
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020553476A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519790A5 (enExample
JP2021519790A (ja
Inventor
ケネス ローソン，
ノエル リーダー，
スミンダ ハプアラチュチ，
ホセ グレゴリオ ラミレス，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2021519790A publication Critical patent/JP2021519790A/ja
Publication of JP2021519790A5 publication Critical patent/JP2021519790A5/ja
Priority to JP2023076664A priority Critical patent/JP2023103323A/ja
Priority to JP2025247999A priority patent/JP2026034591A/ja
Application granted granted Critical
Publication of JP7840636B2 publication Critical patent/JP7840636B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/26—Conditioning of the fluid carrier; Flow patterns
    • G01N30/38—Flow patterns
    • G01N30/46—Flow patterns using more than one column
    • G01N30/461—Flow patterns using more than one column with serial coupling of separation columns
    • G01N30/463—Flow patterns using more than one column with serial coupling of separation columns for multidimensional chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N2030/022—Column chromatography characterised by the kind of separation mechanism
    • G01N2030/027—Liquid chromatography

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020553476A 2018-04-02 2019-04-01 エレヌマブ組成物及びその使用 Active JP7840636B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023076664A JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651651P 2018-04-02 2018-04-02
US62/651,651 2018-04-02
PCT/US2019/025223 WO2019195185A1 (en) 2018-04-02 2019-04-01 Erenumab compositions and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023076664A Division JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用

Publications (3)

Publication Number Publication Date
JP2021519790A JP2021519790A (ja) 2021-08-12
JP2021519790A5 JP2021519790A5 (enExample) 2022-04-07
JP7840636B2 true JP7840636B2 (ja) 2026-04-06

Family

ID=66248665

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020553476A Active JP7840636B2 (ja) 2018-04-02 2019-04-01 エレヌマブ組成物及びその使用
JP2023076664A Withdrawn JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A Pending JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023076664A Withdrawn JP2023103323A (ja) 2018-04-02 2023-05-08 エレヌマブ組成物及びその使用
JP2025247999A Pending JP2026034591A (ja) 2018-04-02 2025-12-12 エレヌマブ組成物及びその使用

Country Status (19)

Country Link
US (2) US11407838B2 (enExample)
EP (1) EP3774881A1 (enExample)
JP (3) JP7840636B2 (enExample)
KR (1) KR20200139720A (enExample)
CN (1) CN111954678A (enExample)
AR (1) AR114722A1 (enExample)
AU (1) AU2019246983B2 (enExample)
BR (1) BR112020019882A2 (enExample)
CA (1) CA3095899A1 (enExample)
CL (2) CL2020002519A1 (enExample)
EA (1) EA202092335A1 (enExample)
IL (1) IL277663A (enExample)
MA (1) MA52202A (enExample)
MX (1) MX2020010320A (enExample)
PH (1) PH12020551618A1 (enExample)
SA (1) SA520420261B1 (enExample)
SG (1) SG11202009629YA (enExample)
TW (1) TWI847980B (enExample)
WO (1) WO2019195185A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3382B1 (ar) * 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2022232376A1 (en) * 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
EP4455163A4 (en) * 2021-12-22 2025-12-24 Chugai Pharmaceutical Co Ltd REDUCED BIOLOGICALLY ACTIVE ANTIBODY VARIANT
CN115819589A (zh) * 2022-10-19 2023-03-21 武汉人福创新药物研发中心有限公司 一种培养基及生产抗cgrpr抗体的方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509344A (ja) 2008-11-20 2012-04-19 ジェネンテック， インコーポレイテッド 治療用タンパク質製剤
JP2015501836A (ja) 2011-12-15 2015-01-19 ハンファ ケミカル コーポレーション 抗体の精製方法
JP2015502959A (ja) 2011-12-07 2015-01-29 アムジェン インコーポレイテッド ＩｇＧ２ジスルフィドアイソフォームの分離
WO2016171742A1 (en) 2015-04-24 2016-10-27 Amgen Inc. Methods for treating or preventing migraine headache
WO2016205037A1 (en) 2015-06-17 2016-12-22 Eli Lilly And Company Anti-cgrp antibody formulation

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1993019180A1 (en) 1992-03-17 1993-09-30 Ciba-Geigy Ag Genetically engineered antibodies
WO1996005221A1 (en) 1994-08-16 1996-02-22 Human Genome Sciences, Inc. Calcitonin receptor
US5785682A (en) 1995-03-22 1998-07-28 Abbott Laboratories Pre-filled syringe drug delivery system
AU6596096A (en) 1996-07-23 1998-02-10 Smithkline Beecham Corporation Calcitonin gene-related peptide receptor component factor (houdc44)
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
BRPI9910332B8 (pt) 1998-05-06 2021-05-25 Genentech Inc método para purificação de um polipeptídio a partir de uma composição
EP1084136B1 (en) 1998-06-01 2004-08-25 Genentech, Inc. Separation of antibody monomers from its multimers by use of ion-exchange chromatography
FR2821080B1 (fr) 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
ATE453661T1 (de) 2001-09-27 2010-01-15 Merck & Co Inc Isolierte dna-moleküle, die für einen humanisierten calcitonin gene-related peptide receptor kodieren, damit verwandte, nichthumane transgene tiere und assayverfahren
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
SI1556020T1 (sl) 2002-08-12 2009-08-31 Birkir Sveinsson Uporaba spojin, ki so antagonisti CGRP, za zdravljenje psoriaze
US20040176577A1 (en) 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
US20060094652A1 (en) 2004-02-11 2006-05-04 Levy Odile E Hybrid polypeptides with selectable properties
AU2005310305A1 (en) 2004-10-22 2006-06-08 Amgen Inc. Methods for refolding polypeptides
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
EP1900374B1 (en) 2005-06-16 2014-03-12 Takayuki Shindo Angiogenetic agent containing adrenomedulin as the active ingredient
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2433251T5 (es) 2005-11-14 2020-03-13 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
WO2007076336A1 (en) 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
KR20090039739A (ko) 2006-08-03 2009-04-22 아스트라제네카 아베 αＶβ６에 대해 작용하는 항체 및 그의 용도
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
ES2584907T3 (es) 2008-03-04 2016-09-30 Labrys Biologics Inc. Métodos para tratamiento del dolor inflamatorio
FR2934597B1 (fr) 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
JO3382B1 (ar) 2008-12-23 2019-03-13 Amgen Inc أجسام مضادة ترتبط مع مستقبل cgrp بشري
BRPI1006519A2 (pt) * 2009-03-06 2016-08-09 Genentech Inc formulação de anticorpos
CN102471377B (zh) * 2009-07-24 2015-04-22 霍夫曼-拉罗奇有限公司 优化抗体的生产
ES2912569T3 (es) 2009-08-28 2022-05-26 Teva Pharmaceuticals Int Gmbh Métodos para tratar el dolor visceral administrando anticuerpos antagonistas dirigidos contra el péptido relacionado con el gen de la calcitonina
DK3272764T3 (da) 2009-12-18 2024-05-06 Novartis Ag Fremgangsmåde til affinitetskromatografi
JOP20190250A1 (ar) 2010-07-14 2017-06-16 Regeneron Pharma صيغ مستقرة تحتوي على الأجسام المضادة لمضاد عامل نمو الأعصاب
RS66303B1 (sr) 2011-05-20 2025-01-31 H Lundbeck As Upotreba anti-cgrp antitela i fragmenata antitela za sprečavanje ili inhibiranje fotofobije ili odbojnosti prema svetlu kod subjekata kojima je to potrebno, naročito kod subjekata koji pate od migrene
JP6292718B2 (ja) 2011-07-01 2018-03-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 凝集ポリペプチドから単量体ポリペプチドを分離するための方法
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
WO2013158279A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Protein purification methods to reduce acidic species
TWI636064B (zh) 2013-03-15 2018-09-21 安美基公司 人類ｐａｃ１抗體
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
EP3019516B1 (en) * 2013-07-12 2018-11-14 H. Hoffnabb-La Roche Ag Elucidation of ion exchange chromatography input optimization
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
MX378344B (es) 2014-03-21 2025-03-10 Teva Pharmaceuticals Int Gmbh Anticuerpos antagonistas dirigidos contra el peptido relacionado con el gen de calcitonina y metodos que usan los mismos.
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX2017003247A (es) * 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012509344A (ja) 2008-11-20 2012-04-19 ジェネンテック， インコーポレイテッド 治療用タンパク質製剤
JP2015502959A (ja) 2011-12-07 2015-01-29 アムジェン インコーポレイテッド ＩｇＧ２ジスルフィドアイソフォームの分離
JP2015501836A (ja) 2011-12-15 2015-01-19 ハンファ ケミカル コーポレーション 抗体の精製方法
WO2016171742A1 (en) 2015-04-24 2016-10-27 Amgen Inc. Methods for treating or preventing migraine headache
WO2016205037A1 (en) 2015-06-17 2016-12-22 Eli Lilly And Company Anti-cgrp antibody formulation

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Wagner-Rousset E. et al., Development of a fast workflow to screen the charge variants of therapeutic antibodies, J. Chromatogr. A, 2017年05月19日, vol.1498, pp.147-154
Yang R. et al., High resolution separation of recombinant monoclonal antibodies by size-exclusion ultra-high performance liquid chromatography (SE-UHPLC), J. Pharm. Biomed. Anal., 2015年05月10日, vol.109, pp.52-61

Also Published As

Publication number Publication date
EP3774881A1 (en) 2021-02-17
US11407838B2 (en) 2022-08-09
BR112020019882A2 (pt) 2021-01-05
TW202003572A (zh) 2020-01-16
TWI847980B (zh) 2024-07-11
WO2019195185A1 (en) 2019-10-10
AU2019246983B2 (en) 2025-12-18
PH12020551618A1 (en) 2021-08-16
US20220348673A1 (en) 2022-11-03
AR114722A1 (es) 2020-10-07
US20190300617A1 (en) 2019-10-03
SA520420261B1 (ar) 2024-05-23
MA52202A (fr) 2021-02-17
JP2023103323A (ja) 2023-07-26
JP2026034591A (ja) 2026-02-27
CA3095899A1 (en) 2019-10-10
KR20200139720A (ko) 2020-12-14
AU2019246983A1 (en) 2020-10-29
CL2023000491A1 (es) 2023-10-13
JP2021519790A (ja) 2021-08-12
SG11202009629YA (en) 2020-10-29
MX2020010320A (es) 2021-01-08
EA202092335A1 (ru) 2021-01-22
CN111954678A (zh) 2020-11-17
IL277663A (en) 2020-11-30
CL2020002519A1 (es) 2021-04-05

Similar Documents

Publication Publication Date Title
US10980885B2 (en) Method of reducing formation of etanercept aggregates or fragments
JP2026034591A (ja) エレヌマブ組成物及びその使用
TWI436776B (zh) Ｆｇｆ２１突變體及其用途
TWI403519B (zh) Ｆｇｆ２１突變體及其用途
US20150329628A1 (en) Liquid formulations for an anti-tnf alpha antibody
RS57013B1 (sr) Korektno savijeni etanercept sa visokom čistoćom i odličnim prinosom
US11000588B2 (en) Etanercept formulations stabilized with sodium chloride
RS53127B2 (sr) Stabilne formulacije proteina
JP2022551622A (ja) インテグリン抗体の安定な製剤
CN112243379A (zh) 稳定的抗体制剂
HK40040918A (en) Erenumab compositions and uses thereof
EA044658B1 (ru) Композиции на основе эренумаба и пути их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220330

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220330

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231207

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240301

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260325

R150 Certificate of patent or registration of utility model

Ref document number: 7840636

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150